Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.
Yang Liu

Main Body of the Abstract
There are unmet clinical  need for the treatment of recurrent and refractory amyloidosis or monoclonal immunoglobulin deposition disease (MIDD). We retrospectively study the efficacy and safety of treatment with bortezomib, pomalidomide, and dexamethasone (BPd) as ≥ second-line treatment for AL amyloidosis (22 cases) or MIDD (two cases). Twenty-four patients were treated for a median of 3.5 cycles (range, 2-8). Differences between involved and uninvolved free light chains (dFLC) were evaluable in 22 patients while serum protein electrophoresis (SPEP) was evaluable for the remaining two patients.  The median dFLC prior to BPd initiation was 109.65 mg/L (range, 35.3-4268.8), which decreased with treatment to a median value of 24.6 mg/L (range, 1.0-2018.8). The overall hematologic response, ≥very good partial response and complete response ratios were 75.0%, 54.2%, and 12.5% respectively. Eight of the 24 patients achieved at least one organ response. Toxicity was acceptable and no patient suffered treatment-related death. In conclusion, our results demonstrated that BPd was a potentially effective regimen, and well tolerated with acceptable side effects for AL amyloidosis and MIDD.

**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Yang Liu

**Main Body of the Abstract**
There are unmet clinical  need for the treatment of recurrent and refractory amyloidosis or monoclonal immunoglobulin deposition disease (MIDD). We retrospectively study the efficacy and safety of treatment with bortezomib, pomalidomide, and dexamethasone (BPd) as ≥ second-line treatment for AL amyloidosis (22 cases) or MIDD (two cases).** **Twenty-four patients were treated for a median of 3.5 cycles (range, 2-8). Differences between involved and uninvolved free light chains (dFLC) were evaluable in 22 patients while serum protein electrophoresis (SPEP) was evaluable for the remaining two patients.  The median dFLC prior to BPd initiation was 109.65 mg/L (range, 35.3-4268.8), which decreased with treatment to a median value of 24.6 mg/L (range, 1.0-2018.8). The overall hematologic response, ≥very good partial response and complete response ratios were 75.0%, 54.2%, and 12.5% respectively. Eight of the 24 patients achieved at least one organ response. Toxicity was acceptable and no patient suffered treatment-related death. In conclusion, our results demonstrated that BPd was a potentially effective regimen, and well tolerated with acceptable side effects for AL amyloidosis and MIDD.

Bortezomib, pomalidomide, and dexamethasone is a potential effective regimen for patients with relapse and refractory AL amyloidosis and monoclonal immunoglobulin deposition disease PA147 (#162)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.